At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GNLX Genelux Corporation
Not Yet Opened 11-04 16:00:00 EST
3.07
-0.14
-4.36%
盘后3.22
+0.15+4.89%
16:19 EST
High3.22Low3.02Vol55.94K
Open3.22D1 Closing3.21Amplitude6.23%
Mkt Cap104.69MTradable Cap78.69MTotal Shares34.10M
T/O173.45KT/O Rate0.22%Tradable Shares25.63M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Genelux: H2 2025 PRROC Data Is A Major Inflection Point
seekingalpha  ·  10-31
Genelux: H2 2025 PRROC Data Is A Major Inflection Point
Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well
Simply Wall St.  ·  10-31
Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well
Genelux Initiated at Buy by Guggenheim
Dow Jones  ·  10-29
Genelux Initiated at Buy by Guggenheim
Guggenheim Initiates Genelux at Buy With $8 Price Target
MT Newswires Live  ·  10-29
Guggenheim Initiates Genelux at Buy With $8 Price Target
Genelux initiated with a Buy at Guggenheim
TIPRANKS  ·  10-29
Genelux initiated with a Buy at Guggenheim
Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp
GuruFocus.com  ·  10-26
Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp
BRIEF-Genelux Corp Announces First Patient Dosed In Phase 2 Trial Evaluating Systemic Therapy With Olvi-Vec In Non-Small Cell Lung Cancer
Reuters  ·  10-23
BRIEF-Genelux Corp Announces First Patient Dosed In Phase 2 Trial Evaluating Systemic Therapy With Olvi-Vec In Non-Small Cell Lung Cancer
Genelux:1st patient dosed in VIRO-25 trial with Olvi-Vec in NSCLC
TIPRANKS  ·  10-23
Genelux:1st patient dosed in VIRO-25 trial with Olvi-Vec in NSCLC
Genelux Corp: Interim Readout Expected Mid-2025
THOMSON REUTERS  ·  10-23
Genelux Corp: Interim Readout Expected Mid-2025
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy With Olvi-Vec in Non-Small Cell Lung Cancer
THOMSON REUTERS  ·  10-23
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy With Olvi-Vec in Non-Small Cell Lung Cancer
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
GlobeNewswire  ·  10-23
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
GlobeNewswire  ·  10-10
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Benzinga  ·  09-04
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
GlobeNewswire  ·  09-04
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
Genelux started at buy by Roth MKM ahead of Olvi-Vec readouts
seekingalpha  ·  08-30
Genelux started at buy by Roth MKM ahead of Olvi-Vec readouts
Roth Capital Initiates Coverage on Genelux With Buy Rating, $10 Price Target
MT Newswires Live  ·  08-28
Roth Capital Initiates Coverage on Genelux With Buy Rating, $10 Price Target
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?
Simply Wall St.  ·  08-17
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?
Maxim Group Sticks to Their Buy Rating for Genelux Corp. (GNLX)
TIPRANKS  ·  08-17
Maxim Group Sticks to Their Buy Rating for Genelux Corp. (GNLX)
North American Morning Briefing: Stocks to Extend Rally as Recession Fears Ease
Dow Jones  ·  08-16
North American Morning Briefing: Stocks to Extend Rally as Recession Fears Ease
Genelux Corp : Maxim Group Cuts Target Price to $10 From $18
THOMSON REUTERS  ·  08-16
Genelux Corp : Maxim Group Cuts Target Price to $10 From $18

Introduction

Company Name.
Genelux Corporation
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Issue price:
--